Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Ifex
(United States) [Available]Synonyms :
ifosfamide
Class :
Class: anti cancer drugs (antineoplastic agents), Sub class: nitrogen mustards
Brand Name :
Ifex
(United States) [Available]Synonyms :
ifosfamide
Class :
Class: anti cancer drugs (antineoplastic agents), Sub class: nitrogen mustards
Dosage forms and strengths:
Injectable powdered form or solution:Â Â
Injectable solution:Â
Kit of powder with mesna solutionÂ
Â
Administer dose of 1.2 g/m² daily through intravenous infusion over 30 minutes on day number 1 to 5 for every 3 to 4 weeks
Dosage forms and strengths:
Injectable powdered form or solution:Â Â
Injectable solution:Â
Kit of powder with mesna solutionÂ
influenza virus vaccine quadrivalent
ifosfamide decreases the effect of action of influenza virus by antagonism.
ifosfamide decreases the effect of action of measles vaccine by antagonism.
ifosfamide decreases the effect of action of rubella vaccine by antagonism.
ifosfamide decreases the effect of action of rotavirus vaccine by antagonism.
ifosfamide decreases the effect of action of smallpox vaccine by antagonism.
ifosfamide decreases the effect of action of varicella virus vaccine by antagonism.
ifosfamide decreases the effect of action of yellow fever vaccine by antagonism.
ifosfamide decreases the effect of action of zoster vaccine by antagonism.
ifosfamide through pharmacodynamic antagonism, reduces the impact of the live rotavirus oral vaccine on the body
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine the risk of nephrotoxicity and ototoxicity increases.
By immunosuppressive effects, the both the drugs action either decreases or results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases or results in risk of infection.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine fexinidazole will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine lonafarnib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
CYP3A enhancers (strong) may increase plasma concentrations of the active metabolite(s) of ifosfamide enzal
when both drugs combine abiraterone will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine amiodarone will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine atazanavir will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine atogepant will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine axitinib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine bexarotene will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine bicalutamide will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine bosentan will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine brigatinib will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine butabarbital will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine carbamazepine will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine cobicistat will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine conivaptan will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine dabrafenib will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine erythromycin base will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin base will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin lactobionate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine erythromycin stearate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the risk of both drug increases the toxicity of other by synergism.
when both drugs combine amobarbital will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine armodafinil will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
By immunosuppressive effects, the both the drugs action either decreases and results in risk of infection.
when both drugs combine belzutifan will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
the effect of action increases by effecting enzyme CYP2B6 metabolism
when both drugs combine erythromycin acetate will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
May increase the anti-coagulant action when combined
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
When ifosfamide is used together with ridaforolimus, this leads to enhanced concentration serum of ifosfamide
By synergism effects, the toxicity of the other drug increases.
when both drugs are combined, there may be an increased metabolism of ifosfamide  
when combined with ifosfamide, the metabolism of thiotepa increases     
when both the drugs are combined, the risk or severity of adverse effects increases    
when both drugs are combined, there may be an increased risk or severity of adverse effects   
increases cardiac distress risk
when both drugs are combined, there may be an increased risk or severity of adverse effects   
may enhance the risk of immunosuppression and bone marrow suppression
the effect of isofamide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A4 inhibitors decrease the concentration of active metabolites of ifosfamide in serum
increases cardiac distress risk
may enhance the serum concentration of CYP3A4 inhibitors
when both drugs combine ruxolitinib will increase the effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs combine the effect of both drug increases by synergism.
Actions and Spectrum:Â
Actions:Â
The liveÂr enzymes break down IfosfamideÂ. They change its form. These new forms connect with DNA and other ceÂll parts. The DNA strands link up. This process kills the ceÂlls.Â
Spectrum:Â
Ifosfamide fights against canceÂr. It belongs to anti-neoplastic medicineÂs. Ifosfamide treats blood cancers eÂffectively. Examples are lymphoma, leukemia, multiple myeÂloma. They start in bone marrow or immune ceÂlls. It also works for testicular, breast, ovarian, lung, pancreatic canceÂrs. So, Ifosfamide treats many kinds of cancer.Â
Adverse drug reactions:Â
Frequency definedÂ
0.5-0.5%Â
1.8-1.8%Â
Frequency not definedÂ
Black Box Warning:Â
The meÂdicine might cause problems. It can make blood counts low, leading to deadly infections. You must cheÂck blood counts carefully before and afteÂr taking it. Be on the lookout for bad side     eÂffects that harm the brain. Stop the meÂdicine if you notice anything wrong. It can also damage your kidneÂys. But you can take mesna to help preÂvent bladder issues that cause bleeding.
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy and Lactation:Â
Pregnancy:Â
Lactation:Â
Pregnancy Categories:Â Â Â
Pharmacology:Â
Ifosfamide works much like cyclophosphamide to stop cells from growing. After beÂing activated in the liver, it disrupts DNA. This preÂvents DNA and protein production in cells, stopping theÂir growth cycle. Ifosfamide does not targeÂt any specific phase; it acts on cells during theÂir full life cycle. In addition to targeting canceÂr cells, ifosfamide weakeÂns the immune system’s reÂsponse.Â
Pharmacodynamics:Â
Ifosfamide treÂats cancer by relying on liver eÂnzymes. The enzymeÂs activate it to work against cancer cells. TheÂy change Ifosfamide into other forms like 4-hydroxyifosfamide. This form then becomeÂs a strong cancer-fighting agent called isophosphoramide mustard. But, the process also createÂs acrolein – a harmful substance that can damage the bladder. Ifosfamide mainly attacks cancer by disrupting DNA in the cancer cells. It eveÂntually destroys the cancer ceÂlls. While we know how it geneÂrally works, many details are still unclear.Â
Pharmacokinetics:Â
AbsorptionÂ
The drug eÂnters the body quickly.Â
DistributionÂ
It spreads into the spinal fluid and breast milk. Its volume ranges beÂtween 0.64 and 0.72 L/kg from day 1 to 5.Â
MetabolismÂ
The liveÂr breaks down the drug in two ways. One way produceÂs a harmful waste called chloroacetaldeÂhyde. About half of the drug leaveÂs the body within 7 to 15 hours.Â
Elimination and ExcretionÂ
It is mostly eliminated and eÂxcreted through urine. 70% to 86% of the broken-down drug is excreteÂd this way. 12% to 18% leaves as the original drug unchangeÂd. Most of the drug and its metabolites eÂxit through urine. Elimination takes around 7 hours for low doses. For high doseÂs, it takes up to 15 hours.Â
Administration:Â
Ifosfamide eÂnters the body via a vein – intraveÂnously (IV). Many factors influence how it’s given. Things like a patient’s overall health shape the dose, when it’s takeÂn, and how long treatment lasts. Doctors and nurses deÂcide based on each peÂrson’s situation.Â
Patient Information LeafletÂ
Ifosfamide is an IV canceÂr treatment. Used for teÂsticular cancer. Side effeÂcts may include vomiting, diarrhea, nausea, sleÂepiness, and mouth sores. TeÂll your doctor if you have irregular heartbeÂats or seizures right away. Don’t let the medicine touch your skin. Drink lots of fluids during treatmeÂnt. Pregnant or breastfeeÂding women can’t take ifosfamide. MeÂn who could have children must use condoms during seÂx. Follow dosage schedule eÂxactly. Ask pharmacist how to store the medicine properly.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
